961 related articles for article (PubMed ID: 12561803)
1. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
2. Uneasy alliance--clinical investigators and the pharmaceutical industry.
Bodenheimer T
N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196
[No Abstract] [Full Text] [Related]
3. NerveCenter: Office of Inspector General warns NIH on lax COI oversight as many academic medical centers look inward.
Samson K
Ann Neurol; 2010 Mar; 67(3):A7-A10. PubMed ID: 20373337
[No Abstract] [Full Text] [Related]
4. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Alván G
Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
[No Abstract] [Full Text] [Related]
5. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
Brand R
State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
[No Abstract] [Full Text] [Related]
6. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
7. Beyond government intervention: drug companies and bioethics.
Dresser R
Am J Bioeth; 2002; 2(3):42-3. PubMed ID: 12230855
[No Abstract] [Full Text] [Related]
8. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
9. Drug companies, doctors and disclosures.
Tuorto S; Chan MK; Adusumilli PS
Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772
[No Abstract] [Full Text] [Related]
10. Prescription-drug prices.
Frank RG
N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
[No Abstract] [Full Text] [Related]
11. Who pays what in drug development.
Love J
Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
[No Abstract] [Full Text] [Related]
12. Academic centers get turnaround advice.
Japsen B
Mod Healthc; 1995 Sep; 25(37):50, 52. PubMed ID: 10151382
[No Abstract] [Full Text] [Related]
13. HHS: POUFA reauthorization good for Americans.
FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
[No Abstract] [Full Text] [Related]
14. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
Tan SY
Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
[No Abstract] [Full Text] [Related]
15. Medical ethics, research and the pharmaceutical industry.
Abud-Mendoza C
Reumatol Clin; 2012; 8(5):233-5. PubMed ID: 22608694
[No Abstract] [Full Text] [Related]
16. Patients, physicians, and clinical trials: the other side of the coins.
Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
[No Abstract] [Full Text] [Related]
17. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
18. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
19. Charities tied to doctors get drug industry gifts.
Abelson R
N Y Times Web; 2006 Jun; ():A1, C4. PubMed ID: 16838451
[No Abstract] [Full Text] [Related]
20. A prescription for better prescriptions.
Woosley RL
Issues Sci Technol; 1994; 10(3):59-66. PubMed ID: 10133487
[No Abstract] [Full Text] [Related]
[Next] [New Search]
